NIAID Plans $20M for New Biodefense Countermeasures, Dx, Rx, Vaccines | GenomeWeb

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases plans to spend up to $20 million in fiscal year 2014 to fund efforts to develop lead candidates for diagnostics, therapeutics, and vaccines, that can be used as biodefense countermeasures against certain pathogens and toxins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.